
Mineralys Therapeutics fell 66.2% from $41.87 to $14.16, behind the S&P 500's +9.7%. Its worst day was Nov 2 (−14.5%), and its low came Nov 18 at $13.78.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Mineralys Therapeutics closed at its highest level of the year, 3.6% above where the year started.
+2.7% · S&P 500 +0.7%
EPS of $-0.40 beat the $-0.54 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−3.0% · S&P 500 −0.6%
Mineralys Therapeutics shares rose 15.2%, while the S&P 500 rose 2.9%.
+15.2%, the year's best day · S&P 500 +2.9%
Mineralys Therapeutics shares rose 11.3%, while the S&P 500 rose 0.8%.
+11.3% · S&P 500 +0.8%
EPS of $-0.47 missed the $-0.45 estimate on $0.00 revenue.
−2.6% · S&P 500 −0.3%
Mineralys Therapeutics shares fell 13.1%, while the S&P 500 fell 0.7%.
−13.1%, on 8M shares, the year's heaviest volume · S&P 500 −0.7%
EPS of $-2.85 missed the $-0.54 estimate on $0.00 revenue.
−1.0% · S&P 500 +0.3%
Mineralys Therapeutics shares rose 13.6%, while the S&P 500 rose 0.4%.
+13.6% · S&P 500 +0.4%
EPS of $-0.64 missed the $-0.54 estimate on $0.00 revenue.
−10.4% · S&P 500 −4.4%
Where it ended: a close of $14.16 on Nov 19, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.67).
Nothing in the past 12 months.
All MLYS dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MLYS and SPY from Benzinga historical bars. Not investment advice.